Daniel Burmester

Daniel Burmester

Auto-generated profile, based on publicly available information

Daniel Burmester

Neurobiology Research Unit and NeuroPharm, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2019 in Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
MMMartin K. Madsen
Martin K. Madsen
PFPatrick M. Fisher
Patrick M. Fisher
DBDaniel Burmester
Daniel Burmester
ADAgnete Dyssegaard
Agnete Dyssegaard
DSDea S. Stenbæk
Dea S. Stenbæk
GKGitte Moos Knudsen
Gitte Moos Knudsen
The main psychedelic component of magic mushrooms is psilocybin, which shows promise as a treatment for depression and other mental disorders. Psychedelic effects are believed to emerge through stimulation of serotonin 2A receptors (5-HT2ARs) by psilocybin’s active metabolite, psilocin. We here report for the first time the relationship between intensity of psychedelic effects, cerebral 5-HT2AR occupancy and plasma levels of psilocin in humans. Eight healthy volunteers underwent positron emission tomography (PET) scans with the 5-HT2AR agonist radioligand [11C]Cimbi-36: one at baseline and one or two additional scans on the same day after a single oral intake of psilocybin (3–30 mg). 5-HT2AR occupancy was calculated as the percent change in cerebral 5-HT2AR binding relative to baseline. Subjective psychedelic intensity and plasma psilocin levels were measured during the scans. Relations between subjective intensity, 5-HT2AR occupancy, and plasma psilocin levels were modeled using non-linear regression. Psilocybin intake resulted in dose-related 5-HT2AR occupancies up to 72%; plasma psilocin levels and 5-HT2AR occupancy conformed to a single-site binding model. Subjective intensity was correlated with both 5-HT2AR occupancy and psilocin levels as well as questionnaire scores. We report for the first time that intake of psilocybin leads to significant 5-HT2AR occupancy in the human brain, and that both psilocin plasma levels and 5-HT2AR occupancy are closely associated with subjective intensity ratings, strongly supporting that stimulation of 5-HT2AR is a key determinant for the psychedelic experience. Important for clinical studies, psilocin time-concentration curves varied but psilocin levels were closely associated with psychedelic experience.

1 April 2020 in European Neuropsychopharmacology
Verified
Journal Article
Closed access
MMMartin Korsbak Madsen
Martin Korsbak Madsen
PFPatrick MacDonald Fisher
Patrick MacDonald Fisher
DSDea Siggaard Stenbæk
Dea Siggaard Stenbæk
SKSara Kristiansen
Sara Kristiansen
DBDaniel Burmester
Daniel Burmester
GKGitte Moos Knudsen
Gitte Moos Knudsen

8 October 2020 in Journal of Psychopharmacology
Verified
Journal Article
Closed access
PDF file
DSDea Siggaard Stenbæk
Dea Siggaard Stenbæk
MMMartin Korsbak Madsen
Martin Korsbak Madsen
BOBrice Ozenne
Brice Ozenne
SKSara Kristiansen
Sara Kristiansen
DBDaniel Burmester
Daniel Burmester
PFPatrick MacDonald Fisher
Patrick MacDonald Fisher
Background: Psilocybin is a serotonergic psychedelic with psychoactive effects mediated by serotonin 2A receptor (5-HT2AR) activation. It produces an acute psychedelic altered state of consciousness with a unique phenomenology that can be temporally characterized by three intensity phases: onset of psychoactive effect, a peak plateau and return to normal consciousness. Aims: We evaluated whether pre-drug brain 5-HT2AR binding predicted the three phases of psilocybin subjective drug intensity (SDI) and retrospective self-report of mystical type experiences in healthy individuals. Method: Sixteen participants completed a pre-drug [11C]Cimbi-36 positron emission tomography scan to assess 5-HT2AR binding. On a separate day, participants completed a single psilocybin session (oral dose range 0.2–0.3 mg/kg), during which SDI was assessed every 20 min. The Mystical Experience Questionnaire (MEQ) was completed at the end of the session. The three SDI phases were modelled using segmented linear regressions. We evaluated the associations between neocortex 5-HT2AR binding and SDI/MEQ outcomes using linear regression models. Results: Neocortex 5-HT2AR was statistically significantly negatively associated with peak plateau duration and positively with time to return to normal waking consciousness. It was also statistically significantly negatively associated with MEQ total score. Conclusion: This is the first study to investigate how individual brain 5-HT2AR binding predicts subjective effects of a single dose of psilocybin. Our findings reinforce the role of cerebral 5-HT2AR in shaping the temporal and mystical features of the psychedelic experience. Future studies should examine whether individual brain levels of 5-HT2AR have an impact on therapeutic outcomes in clinical studies.

6 December 2022 in Comprehensive Psychoneuroendocrinology
Verified
Journal Article
Open access
DBDaniel Rødbro Burmester
Daniel Rødbro Burmester
MMMartin Korsbak Madsen
Martin Korsbak Madsen
ASAttila Szabo
Attila Szabo
SASagar Sanjay Aripaka
Sagar Sanjay Aripaka
DSDea Siggaard Stenbæk
Dea Siggaard Stenbæk
PFPatrick MacDonald Fisher
Patrick MacDonald Fisher
Psilocybin is a serotonergic psychedelic that has gained prominent attention recently as a potential therapeutic for neuropsychiatric disorders including Major Depressive Disorder. Pre-clinical and initial studies in humans suggest that serotonin 2A receptor agonists, including serotonergic psychedelics, have anti-inflammatory effects. This may contribute to its therapeutic effects as previous studies indicate a link between neuropsychiatric disorders and inflammatory processes. However, the effect of psilocybin on biomarkers of inflammation has not been evaluated in humans. Investigate the effect of a single dose of psilocybin on peripheral biomarkers of inflammation in healthy humans. Blood samples were collected from 16 healthy participants before and one day after the administration of a single oral dose of psilocybin (mean dose: 0.22 mg/kg) and subsequently analyzed for concentrations of high-sensitivity C-reactive protein (hsCRP), tumor-necrosis-factor (TNF) and soluble urokinase plasminogen activator receptor (suPAR). Change in inflammatory markers was evaluated using a paired t-test where p < 0.05 was considered statistically significant. We did not observe statistically significant changes in any of the above biomarkers of inflammation (all Cohen's d ≤ 0.31; all p ≥ 0.23). Our data do not support that a single dose of psilocybin reduces biomarkers of inflammation in healthy individuals one day after administration. Nevertheless, we suggest that future studies consider additional markers of inflammation, including markers of neuroinflammation, and evaluate potential anti-inflammatory effects of psilocybin therapy in clinical cohorts where more prominent effects may be observable.

11 January 2019 in Human Brain Mapping
Verified
Journal Article
Closed access
PDF file
DSDea Siggaard Stenbæk
Dea Siggaard Stenbæk
SKSara Kristiansen
Sara Kristiansen
DBDaniel Burmester
Daniel Burmester
MMMartin Korsbak Madsen
Martin Korsbak Madsen
VFVibe Gedsoe Frokjaer
Vibe Gedsoe Frokjaer
PFPatrick MacDonald Fisher
Patrick MacDonald Fisher